NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

膀胱過動症治療藥的全球市場的預測:處方藥、OTC藥

Global Overactive Bladder Treatment Market 2018-2028: Prescription Drugs, OTC Drugs, Short-term Therapy, Long-term Therapy

出版商 Visiongain Ltd 商品編碼 660935
出版日期 內容資訊 英文 161 Pages
商品交期: 最快1-2個工作天內
價格
膀胱過動症治療藥的全球市場的預測:處方藥、OTC藥 Global Overactive Bladder Treatment Market 2018-2028: Prescription Drugs, OTC Drugs, Short-term Therapy, Long-term Therapy
出版日期: 2018年05月25日內容資訊: 英文 161 Pages
簡介

全球膀胱過動症治療藥的市場在預測期間內預計以2.4%的年複合成長率成長。

本報告提供全球膀胱過動症治療藥的市場調查,疾病、診斷、治療概要,藥物類別和藥物簡介,各處方藥/OTC藥區分、治療期間、地區、主要國家趨勢與市場規模的變化與預測,市場成長的各種影響因素及市場機會分析,各地區的償付趨勢,主要企業簡介等彙整。

第1章 報告概要

第2章 簡介:膀胱過動症

  • 診斷方法
    • 尿液檢查
    • 尿路動力學檢驗
    • 尿流檢測 (尿流速測定)
    • 咳嗽壓力測試
    • 前列腺、骨盆檢驗
    • 膀胱尿道造影
  • 藥物類別
    • 抗毒蕈鹼劑
    • β-3腎上腺素受體受體激動劑
  • 治療方法
    • 行動療法
    • 骨盆底筋物理治療
    • 電刺激
  • 膀胱過動症的盛行率與負擔
  • 藥物簡介
    • Darifenacin
    • Fesoterodine
    • Oxybutynin
    • Solifenacin
    • Tolterodine
    • Trospium
    • 肉毒桿菌注射

第3章 全球膀胱過動症治療藥市場:市場預測

第4章 全球膀胱過動症治療藥市場分析、預測:各處方藥/OTC藥

  • 市場預測
    • 處方藥
    • OTC藥
    • 市場佔有率

第5章 全球膀胱過動症治療藥市場分析、預測:各治療期間

  • 市場預測
    • 短期
    • 長期
    • 市場佔有率

第6章 市場成長的促進因素、阻礙要素、市場趨勢

第7章 全球膀胱過動症治療藥市場分析、預測:主要國家市場

  • 市場成果、預測:各地區
  • 美國
  • 歐盟5國
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
  • 金磚四國
    • 巴西
    • 俄羅斯
    • 中國
    • 印度
  • 日本
  • 澳洲
  • 加拿大

第8章 主要企業

  • 競爭模式
  • Astellas Pharma Inc.
  • Pfizer
  • Allergan
  • Sanofi
  • Medtronic
  • Apotex
  • Mylan

第9章 膀胱過動症治療藥

第10章 定性分析

  • SWOT分析
  • 波特的五力分析
  • 市場成長的促進因素
  • 市場成長的阻礙因素
  • 市場機會
  • 償付
    • NICE (英國)
    • SMC (蘇格蘭)
    • PBAC (澳洲)
    • CADTH (加拿大)
    • G-BA (德國)
    • HAS (法國)
  • 償付方案
    • 日本
    • 美國
    • 歐洲

第11章 其他有力供應商

第12章 總論

目錄
Product Code: PHA0311

The global overactive bladder treatment market is expected to grow at a CAGR of 2.4% in the first half of the forecast period. In 2017, the prescription drugs segment held 96% of the market.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 161-page report you will receive 136 charts- all unavailable elsewhere.

The 161-page report provides clear detailed insight into the global overactive bladder treatment market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

Global Overactive Bladder Treatment market forecasts from 2018-2028

This report also breaks down the revenue forecast for the global overactive bladder treatment market by these submarkets:

  • Prescription Drugs Market Forecast 2018-2028
  • OTC Drugs Market Forecast 2018-2028
  • Short-term Therapy Market Forecast 2018-2028
  • Long-term Therapy Market Forecast 2018-2028

This report provides individual revenue forecasts to 2028 for these regional and national markets:

  • US
  • EU5: Germany, France, UK, Italy, Spain
  • BRIC: Brazil, Russia, India, China
  • Japan
  • RoW: South Korea, Australia, Canada, MENA, Others

Our study gives qualitative analysis of the overactive bladder treatment market:

  • Drivers and Restraints
  • Porter's Five Forces Analysis
  • SWOT Analysis
  • Trends and Opportunities
  • Reimbursement scenarios in the US, Europe and Japan

Our study discusses the selected leading companies that are the major players in the overactive bladder treatment market:

  • Allergan
  • Apotex
  • Astellas
  • Medtronic
  • Mylan
  • Pfizer
  • Sanofi

Visiongain's study is intended for anyone requiring commercial analyses for the global overactive bladder treatment market. You find data, trends and predictions.

Buy our report today ‘Global Overactive Bladder Treatment Market 2018-2028: Prescription Drugs, OTC Drugs, Short-term Therapy, Long-term Therapy ’.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Why You Should Read This Report
  • 1.2. How This Report Delivers
  • 1.3. Key Questions Answered by This Analytical Report Include:
  • 1.4. Who is This Report For?
  • 1.5. Methodology
    • 1.5.1. Primary Research
    • 1.5.2. Secondary Research
    • 1.5.3. Market Evaluation & Forecasting Methodology
  • 1.6. Frequently Asked Questions (FAQ)
  • 1.7. Associated Visiongain Reports
  • 1.8. About Visiongain

2. Introduction to Overactive Bladder

  • 2.1. Available Diagnosis for Overactive Bladder Symptoms
    • 2.1.1. Urinalysis
    • 2.1.2. Urodynamic Tests
    • 2.1.3. Uroflowmetry
    • 2.1.4. Cough Stress Test
    • 2.1.5. Prostate or Pelvic exam
    • 2.1.6. Cystourethrogram
  • 2.2. Class of Drugs
    • 2.2.1. Anti-muscarinic Agent
    • 2.2.2. Beta-3-Adrenergic Receptor Agonist
  • 2.3. Available Treatments for Overactive Bladder
    • 2.3.1. Behavioural Therapy
    • 2.3.2. Pelvic Floor Physiotherapy
    • 2.3.3. Electrical Stimulation
  • 2.4. The Prevalence and Burden of Overactive Bladder
  • 2.5. Drug Profiles
    • 2.5.1. Darifenacin
    • 2.5.2. Fesoterodine
    • 2.5.3. Worldwide Sales of Toviaz 2016 vs 2017
    • 2.5.4. Oxybutynin
    • 2.5.5. Solifenacin
    • 2.5.6. Tolterodine
    • 2.5.7. Trospium
    • 2.5.8. Botox Injection

3. Global Overactive Bladder Therapeutic Market Forecast 2018-2028

4. Global Overactive Bladder Therapeutic Market 2018-2028: Submarket Segmentation by Prescription and OTC Drugs

  • 4.1. Forecast by Prescription vs OTC Drugs 2018-2028
    • 4.1.1. Global Overactive Bladder Prescription Drugs Market 2018-2028
    • 4.1.2. Global Overactive Bladder OTC Drugs Market 2018-2028
    • 4.1.3. Market Share Forecast - Overactive Bladder Therapeutic market by Prescription vs OTC Drugs 2018-2028

5. Global Overactive Bladder Therapeutic Market 2018-2028: Submarket Segmentation by Duration of Therapy 2018-2028

  • 5.1. Forecast by Duration of Therapy 2018-2028
  • 5.2. Global Overactive Short-term Overactive Bladder Therapy Market 2018-2028
  • 5.3. Global Overactive Bladder Long-term Therapy Market 2018-2028
  • 5.4. Market Share Forecast by Duration of Therapy 2018-2028

6. Global Overactive Bladder Therapeutic Market: Drivers, Restraints and Trends

7. Global Overactive Bladder Therapeutic Market 2018-2028: Leading National Markets

  • 7.1. Geographical Breakdown of Global Overactive Bladder Therapeutic Market, 2017
    • 7.1.1. Breakdown of Global Overactive Bladder Therapeutic Market by Region, 2017
    • 7.1.2. Breakdown of Global Overactive Bladder Therapeutic Market by Country, 2017
    • 7.1.3. Region-wise Forecast of Global Overactive Bladder Therapeutic Market, 2018-2028
  • 7.2. Global Overactive Bladder Therapeutic Market in the US, 2017
    • 7.2.1. Healthcare Scenario in the US
    • 7.2.2. Economic Impacts of Overactive Bladder
    • 7.2.3. US Overactive Bladder Therapeutic Market 2018-2028
  • 7.3. EU5. Overactive Bladder Therapeutic Market 2018-2028
    • 7.3.1. The UK Overactive Bladder Therapeutic Market 2018-2028
    • 7.3.2. Germany Overactive Bladder Therapeutic Market 2018-2028
    • 7.3.3. France Overactive Bladder Therapeutic Market 2018-2028
    • 7.3.4. Italy Overactive Bladder Therapeutic Market 2018-2028
    • 7.3.5. Spain Overactive Bladder Therapeutic Market 2018-2028
  • 7.4. BRIC Overactive Bladder Therapeutic Market 2018-2028
    • 7.4.1. Brazil Overactive Bladder Therapeutic Market 2018-2028
    • 7.4.2. Russia Overactive Bladder Therapeutic Market 2018-2028
    • 7.4.3. China Overactive Bladder Therapeutic Market 2018-2028
    • 7.4.4. India Overactive Bladder Therapeutic Market 2018-2028
  • 7.5. Japan Overactive Bladder Therapeutic Market 2018-2028
  • 7.6. Australia Overactive Bladder Therapeutic Market 2018-2028
  • 7.7. Canada Overactive Bladder Therapeutic Market 2018-2028

8. Global Overactive Bladder Therapeutic Market: Leading Companies

  • 8.1. Competitive Scenarios
  • 8.2. Astellas
  • 8.3. Pfizer
  • 8.4. Allergan
  • 8.5. Sanofi
  • 8.6. Medtronic
  • 8.7. Apotex
  • 8.8. Mylan

9. Drugs to Treat Overactive Bladder

10. Global Overactive Bladder Therapeutic Market: Qualitative Analysis

  • 10.1. SWOT Analysis
  • 10.2. Porter's Five Forces Analysis
  • 10.3. Overall Global Overactive Bladder Therapeutic Market Drivers
    • 10.3.1. Number of Elderly Patients Expected to Rise
    • 10.3.2. Opportunities from the Long Pipeline Will Drive Growth
    • 10.3.3. Focus on early diagnosis will increase the number of patients in the market
  • 10.4. Restraints on Growth in the Overactive Bladder Therapeutic Market
    • 10.4.1. Low Awareness
    • 10.4.2. Competition from Generics Will Increase
    • 10.4.3. High Number of Products Will Saturate Market
    • 10.4.4. Lack of reimbursement for Diagnosis and therapeutic products will hinder the market growth
  • 10.5. Opportunities on Growth in the Overactive Bladder Therapeutic Market
    • 10.5.1. Need for Effective Drugs with Better Safety Profiles
  • 10.6. Reimbursement
    • 10.6.1. NICE (UK)
    • 10.6.2. SMC (Scotland)
    • 10.6.3. PBAC (Australia)
    • 10.6.4. CADTH (Canada)
    • 10.6.5. G-BA (Germany)
    • 10.6.6. HAS (France)
  • 10.7. Reimbursement Scenarios in various Countries
    • 10.7.1. Japan
    • 10.7.2. The US
    • 10.7.3. Europe

11. Overactive Bladder Therapeutic Market: Other Prominent Vendors

12. Conclusion

Appendices

  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain report evaluation form

List of Tables

  • Table 3.1: Global Overactive Bladder Therapeutic Market Forecast 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.1: Global Overactive Bladder Therapeutic Market Segmentation by Prescription and OTC Drugs 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.2: Global Overactive Bladder Therapeutic Market Segmentation by Prescription and OTC Drugs 2017-2028: AGR (%)
  • Table 4.3: Global Overactive Bladder Prescription Drugs Market 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.4: Global Overactive Bladder OTC Drugs Market 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.5: Global Overactive Bladder Therapeutic market by Prescription vs OTC Drugs 2018-2028: Market Share (%)
  • Table 5.1: Global Overactive Bladder Therapeutic Market Segmentation by Duration of Therapy 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.2: Global Overactive Bladder Therapeutic Market Segmentation by Duration of Therapy 2017-2028: AGR (%)
  • Table 5.3: Global Overactive Bladder Short-term Therapy Market 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.4: Global Overactive Bladder Long-term Therapy Market 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.5: Global Overactive Bladder Therapeutic Market by Duration of Therapy 2017-2028: Market Share Forecast 2018-2028 (%)
  • Table 7.1: Global Overactive Bladder Therapeutic Market by Region: Revenue ($m), and Market Share (%), 2017
  • Table 7.2: Global Overactive Bladder Therapeutic Market by Country: Revenue ($m), and Market Share (%), 2017
  • Table 7.3: Global Overactive Bladder Therapeutic Market Forecast by Region: Revenue ($m), AGR (%), CAGR (%), 2017-2028
  • Table 7.4: Global Overactive Bladder Therapeutic Market by Region: AGR 2017-2028 (%)
  • Table 7.5: Global Overactive Bladder Therapeutic Market Forecast 2017-2028: AGR (%)
  • Table 7.6: Overactive Bladder Therapeutic Market Forecast in the US 2017-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 7.7: EU Overactive Bladder Therapy Market by Country 2017: Revenue ($m), Market Share (%)
  • Table 7.8: Overactive Bladder Therapeutic Market Forecast in EU5 Region: Revenue ($m), AGR (%), CAGR (%), 2017-2028
  • Table 7.9: Overactive Bladder Therapeutic Market by EU Region: Market Share Forecast 2018-2028 (%)
  • Table 7.10: Overactive Bladder Therapeutic Market Forecast by EU5 Region:
  • Table 7.11: Overactive Bladder Therapeutic Market Forecast by EU5 Region: AGR (%) -2017-2028
  • Table 7.12: Overactive Bladder Therapeutic Market Forecast in the UK: Revenue ($m), AGR (%), CAGR (%), 2017-2028
  • Table 7.13: Overactive Bladder Therapeutic Market Forecast in Germany: Revenue ($m), AGR (%), CAGR (%), 2017-2028
  • Table 7.14: Overactive Bladder Therapeutic Market Forecast in France: Revenue ($m), AGR (%), CAGR (%), 2017-2028
  • Table 7.15: Overactive Bladder Therapeutic Market Forecast in Italy: Revenue ($m), AGR (%), CAGR (%), 2017-2028
  • Table 7.16: Overactive Bladder Therapeutic Market Forecast in Spain: Revenue ($m), AGR (%), CAGR (%), 2017-2028
  • Table 7.17: Overactive Bladder Therapeutic Market Forecast in BRIC Region: Revenue ($m), AGR (%), CAGR (%), 2017-2028
  • Table 7.18: Overactive Bladder Therapeutic Market Forecast in Brazil Region: Revenue ($m), AGR (%), CAGR (%), 2017-2028
  • Table 7.19: Overactive Bladder Therapeutic Market Forecast in Russia: Revenue ($m), AGR (%), CAGR (%), 2017-2028
  • Table 7.20: Overactive Bladder Therapeutic Market Forecast in China: Revenue ($m), AGR (%), CAGR (%), 2017-2028
  • Table 7.21: Overactive Bladder Therapeutic Market Forecast in India: Revenue ($m), AGR (%), CAGR (%), 2017-2028
  • Table 7.22: Overactive Bladder Therapeutic Market Forecast in Japan: Revenue ($m), AGR (%), CAGR (%), 2017-2028
  • Table 7.23: Overactive Bladder Therapeutic Market Forecast in Australia: Revenue ($m), AGR (%), CAGR (%), 2017-2028
  • Table 7.24: Overactive Bladder Therapeutic Market Forecast in Canada: Revenue ($m), AGR (%), CAGR (%), 2017-2028
  • Table 8.1: Astellas: Company Overview
  • Table 8.2: Pfizer: Company Overview
  • Table 8.3: Sanofi: Company Overview
  • Table 8.4: Medtronic: Company Overview
  • Table 8.5: Medtronic Revenue FY2013 - FY2017
  • Table 8.6: Medtronic: Urological and Urogynecological Products
  • Table 8.7: Apotex: Company Overview
  • Table 8.8: Mylan: Company Overview
  • Table 9.1: Drugs to Treat Overactive Bladder
  • Table 10.1: HTA Agencies
  • Table 11.1: Other Prominent Vendors

List of Figures

  • Figure 2.1: Prevalence of Overactive Bladder Syndrome versus Other Health Conditions
  • Figure 2.2: Sales ($m) of Toviaz 2016 versus 2017
  • Figure 3.1: Global Overactive Bladder Therapeutic Market 2017-2028: Revenue ($m), AGR (%)
  • Figure 4.1: Global Market Segmentation by Prescription and OTC Drugs, Revenue 2017 ($m)
  • Figure 4.2: Global Market Segmentation by Prescription and OTC Drugs, Revenue 2017 (%)
  • Figure 4.3: Global Overactive Bladder Therapeutic Market Segmentation by Prescription and OTC Drugs 2017-2028: Revenue ($m)
  • Figure 4.4: Global Overactive Bladder Therapeutic Market Segmentation by Prescription and OTC Drugs, Market share 2017 (%)
  • Figure 4.5: Global Overactive Bladder Therapeutic Market Segmentation by Prescription and OTC Drugs 2017, 2023 and 2028: Revenue ($m)
  • Figure 4.6: Global Overactive Bladder Therapeutic Market Segmentation by Prescription and OTC Drugs 2017-2028: AGR (%)
  • Figure 4.7: Global Overactive Bladder Prescription Drugs Market 2017-2028: Revenue ($m), AGR (%)
  • Figure 4.8: Global Overactive Bladder OTC Drugs Market 2017-2028: Revenue ($m), AGR (%)
  • Figure 4.9: Global Overactive Bladder Therapeutic market by Prescription vs OTC Drugs 2018-2028: Market Share (%)
  • Figure 4.10: Global Overactive Bladder Therapeutic market by Prescription vs OTC Drugs 2017 (%)
  • Figure 4.11: Global Overactive Bladder Therapeutic market by Prescription vs OTC Drugs 2023 (%)
  • Figure 4.12: Global Overactive Bladder Therapeutic market by Prescription vs OTC Drugs 2028 (%)
  • Figure 5.1: Global Overactive Drugs Market Segmentation by Duration of Therapy, Revenue 2017 ($m)
  • Figure 5.2: Global Overactive Drugs Market Segmentation by Duration of Therapy, Revenue 2017 (%)
  • Figure 5.3: Global Overactive Bladder Therapeutic Market Segmentation by Duration of Therapy 2017-2028: Revenue ($m)
  • Figure 5.4: Global Overactive Bladder Therapeutic Market Segmentation by Duration of Therapy: Revenue ($m) 2017 and 2028
  • Figure 5.5: Global Overactive Bladder Therapeutic Market Segmentation by Duration of Therapy 2017-2028: AGR (%)
  • Figure 5.6: Global Overactive Bladder Short-term Therapy Market 2017-2028: Revenue ($m), AGR (%)
  • Figure 5.7: Global Overactive Bladder Long-term Therapy Market 2017-2028: Revenue ($m), AGR (%)
  • Figure 5.8: Global Overactive Bladder Therapeutic Market by Duration of Therapy 2017: Market Share (%)
  • Figure 5.9: Global Overactive Bladder Therapeutic Market Segmentation by Duration of Therapy, Market Share Forecast 2017, 2023, 2028 (%)
  • Figure 5.10: Global Overactive Bladder Therapeutic Market Segmentation by Duration of Therapy, Market Share Forecast 2017 (%)
  • Figure 5.11: Global Overactive Bladder Therapeutic Market Segmentation by Duration of Therapy, Market Share Forecast 2023 (%)
  • Figure 5.12: Global Overactive Bladder Therapeutic Market Segmentation by Duration of Therapy, Market Share Forecast 2028 (%)
  • Figure 6.1: Trends in Global Overactive Bladder Therapeutic Market
  • Figure 6.2: Trends in Global Overactive Bladder Therapeutic Market
  • Figure 7.1: Global Overactive Bladder Therapeutic Market Segmentation by Region/Country
  • Figure 7.2: Global Overactive Bladder Therapeutic Market by Region: Revenue ($m)
  • Figure 7.3: Global Overactive Bladder Therapeutic Market by Region: Market Share 2017 (%)
  • Figure 7.4: Global Overactive Bladder Therapeutic Market by Country: Revenue ($m)
  • Figure 7.5: Global Overactive Bladder Therapeutic Market by Country: Market Share (%)
  • Figure 7.6: Global Overactive Bladder Therapeutic Market Forecast by Region: Revenue ($m), 2017-2028
  • Figure 7.7: Global Overactive Bladder Therapeutic Market Forecast by Region 2017, 2023, 2028: Revenue ($m)
  • Figure 7.8: Global Overactive Bladder Therapeutic Market by Region: AGR 2017-2028 (%)
  • Figure 7.9: Global Overactive Bladder Therapeutic Market Forecast 2017-2028: AGR (%)
  • Figure 7.10: Global Overactive Bladder Therapeutic Market Share Forecast 2018 (%)
  • Figure 7.11: Global Overactive Bladder Therapeutic Market Share Forecast 2023 (%)
  • Figure 7.12: Global Overactive Bladder Therapeutic Market Share Forecast 2028 (%)
  • Figure 7.13: Overactive Bladder Therapeutic Market in the US: Market Share (%), 2017
  • Figure 7.14: Overactive Bladder Therapeutic Market Forecast in the US 2017-2028: Revenue ($m), AGR (%)
  • Figure 7.15: Overactive Bladder Therapeutic Market in the EU5 2017: Global Market Share (%)
  • Figure 7.16: Overactive Bladder Therapeutic Market in the EU5 Countries 2016: Market Share (%)
  • Figure 7.17: Overactive Bladder Therapeutic Market Forecast in the EU5 2017-2028: Revenue ($m), AGR (%)
  • Figure 7.18: Overactive Bladder Therapeutic Market Forecast in EU5 Region: Revenue 2017-2028: Revenue ($m)
  • Figure 7.19: Overactive Bladder Therapeutic Market Forecast in the EU5 Countries 2017 and 2028: Revenue ($m)
  • Figure 7.20: Overactive Bladder Therapeutic Market by EU5 Region: Market Share Forecast 2018-2028 (%)
  • Figure 7.21: Overactive Bladder Therapeutic Market in the EU5 2028: Global Market Share (%)
  • Figure 7.22: Overactive Bladder Therapeutic Market Forecast by EU5 Region: Market Share 2017(%)
  • Figure 7.23: Overactive Bladder Therapeutic Market Forecast by EU5 Region: Market Share 2023 (%)
  • Figure 7.24: Overactive Bladder Therapeutic Market Forecast by EU5 Region: Market Share 2028 (%)
  • Figure 7.25: Overactive Bladder Therapeutic Market Forecast by EU5 Region
  • Figure 7.26: Overactive Bladder Therapeutic Market Forecast by EU5 Region: AGR 2017-2028 (%)
  • Figure 7.27: Overactive Bladder Therapeutic Market Forecast in the UK: Revenue ($m), AGR (%), 2017-2028
  • Figure 7.28: Overactive Bladder Therapeutic Market Forecast in Germany: Revenue ($m), AGR (%), 2017-2028
  • Figure 7.29: Overactive Bladder Therapeutic Market Forecast in France: Revenue ($m), AGR (%), 2017-2028
  • Figure 7.30: Overactive Bladder Therapeutic Market Forecast in Italy: Revenue ($m), AGR (%), 2017-2028
  • Figure 7.31: Overactive Bladder Therapeutic Market Forecast in Spain: Revenue ($m), AGR (%), 2017-2028
  • Figure 7.32: Overactive Bladder Therapeutic Market Forecast in the BRIC Countries 2017-2028: Revenue ($m)
  • Figure 7.33: Overactive Bladder Therapeutic Market Forecast in the BRIC Countries: Revenue ($m) 2017, 2013 and 2028:
  • Figure 7.34: Overactive Bladder Therapeutic Market Forecast by BRIC Region: Global Market Share 2017(%)
  • Figure 7.35: Overactive Bladder Therapeutic Market Forecast by BRIC Region: Market Share 2017 (%)
  • Figure 7.36: Overactive Bladder Therapeutic Market Forecast by BRIC Region: Market Share 2028 (%)
  • Figure 7.37: Overactive Bladder Therapeutic Market Forecast by BRIC Region: Global Market Share 2028(%)
  • Figure 7.38: Overactive Bladder Therapeutic Market Forecast in Brazil: Revenue ($m), AGR (%), 2017-2028
  • Figure 7.39: Overactive Bladder Therapeutic Market Forecast in Russia: Revenue ($m), AGR (%), 2017-2028
  • Figure 7.40: Overactive Bladder Therapeutic Market Forecast in China: Revenue ($m), AGR (%), 2017-2028
  • Figure 7.41: Overactive Bladder Therapeutic Market Forecast in India: Revenue ($m), AGR (%), 2017-2028
  • Figure 7.42: Overactive Bladder Therapeutic Market in Japan: 2017 Revenue ($m), Market Share %
  • Figure 7.43: Overactive Bladder Therapeutic Market Forecast in Japan: Revenue ($m), AGR (%), 2017-2028
  • Figure 7.44: Overactive Bladder Therapeutic Market in Australia: 2017 Revenue ($m), Market Share %
  • Figure 7.45: Overactive Bladder Therapeutic Market Forecast in Australia: Revenue ($m), AGR (%), 2017-2028
  • Figure 7.46: Overactive Bladder Therapeutic Market in Canada: 2017 Revenue ($m), Market Share %
  • Figure 8.1: Astellas Sales by Geographic area, Market Share (%), 2017
  • Figure 8.2: Astellas Sales by Therapeutic area, Market Share (%), 2017
  • Figure 8.3: Astellas: SWOT Analysis
  • Figure 8.4: Sales of Pfizer by Geographical region
  • Figure 8.5: Pfizer: SWOT Analysis
  • Figure 8.6: Allergan: SWOT Analysis
  • Figure 8.7: Sanofi: SWOT Analysis
  • Figure 8.8: Medtronic: SWOT Analysis
  • Figure 8.9: Apotex: SWOT Analysis
  • Figure 8.10: A: SWOT Analysis
  • Figure 10.1: Global Overactive Bladder Therapeutic Market: SWOT Analysis
  • Figure 10.2: Global Overactive Bladder Therapeutic Market: Porter's Five Forces Analysis
  • Figure 12.1: Global Overactive Bladder Therapeutic Market Forecast 2017-2028: Revenue ($m), AGR (%)
  • Figure 12.2: Global Overactive Bladder Therapeutic Market by Region: Market Share 2017 (%)
  • Figure 12.3: Prevalence of Overactive Bladder Syndrome versus Other Major Health Condition

Companies Listed

  • Addex Therapeutics
  • Allergan
  • AltheRx Pharmaceuticals
  • American Oriental Bioengineering
  • Amerifit
  • Antares Pharma
  • Apogepha Arzneimittel
  • Apotex
  • Astellas
  • Aventis
  • Bayer
  • Boehringer Ingelheim
  • Catalent Pharma Solutions
  • CSL
  • Eli Lilly
  • Endo international
  • FemmePharma
  • Ferring Pharmaceuticals
  • Galen Ltd
  • Hisamitsu Pharmaceutical
  • Hydra Biosciences
  • Ion Channel Innovations
  • Janssen
  • Kissei Pharmaceutical Co., Ltd.
  • Kwang Dong Pharmaceutical
  • KYORIN Pharma
  • Lipella Pharmaceuticals
  • Matrix Laboratories Limited
  • Medtronic
  • Merck KGaA
  • Merus Labs Luxco S.a.R.L.
  • Mylan
  • Novartis
  • Ono Pharmaceuticals
  • Paddock Laboratories
  • Paladin
  • Pfizer
  • Ranbaxy Laboratories
  • Recordati Pharmaceuticals Ltd
  • Sanofi
  • Sanofi Espoir Foundation
  • Sanofi Synthelabo
  • Schwarz Pharma AG
  • Speciality European Pharma Ltd
  • Warner Chilcott
  • Watson Pharmaceuticals, Inc.
  • Yamanouchi Pharma

List of Organisations Mentioned in the Report:

  • Agência Nacional de Vigilância Sanitária (ANVISA)
  • Canadian Agency for Drugs and Technologies in Health (CADTH)
  • Gemeinsamer Bundesausschuss (G-BA)
  • Haute Autorité de santé (HAS)
  • Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWIG)
  • International Continence Society
  • Japan Pharmaceutical and Medical Devices Agency (PMDA)
  • Medicare
  • Ministry of Health, Labor and Welfare (MHLW)
  • National Institute for Health and Care Excellence (NICE)
  • Pharmaceutical Benefits Advisory Committee (PBAC)
  • Scottish Medicines Consortium (SMC)
  • The American Urological Association
  • US Food and Drug Administration (FDA)
  • World Health Organization (WHO)